

# ***Diabetes mellitus as an independent predictor of COVID-19 outcomes***

## ***Le diabète sucré en tant que facteur prédictif indépendant du pronostic de l'infection au COVID-19***

**Authors:** Houda Ben Soltane <sup>1,2</sup>, Ons Haddaji <sup>2</sup>, Asma Ammar <sup>3,2</sup>, Mariem Khrouf<sup>1,2</sup>, Fatma Kacem <sup>2</sup>, Cyrine Zegdane <sup>2</sup>, Yosra Hasni<sup>4,2</sup>, Zied Mezgar <sup>1,2</sup>.

*1: Emergency Department Farhat Hached University Hospital, of Sousse, Tunisia*

*2: Faculty of Medicine of Sousse; 4002. University of Sousse; Tunisia.*

*3: Infection Prevention and Control department, Farhat Hached university hospital, Tunisia*

*4: Endocrinology department, Farhat Hached university hospital, Tunisia*

**Corresponding author:** Ons Haddaji Email: [ons.haddaji.s@gmail.com](mailto:ons.haddaji.s@gmail.com) Phone number: 58646146

### **Abstract**

**Introduction:** COVID-19 is a respiratory disease that can range from asymptomatic to critical or fatal. The severity of the clinical presentation depends on various factors, including comorbidities such as diabetes, which has been shown to be strongly associated with a more severe course and higher mortality rate.

**Objectives:** This study aims to describe the particularities of COVID-19 infection in diabetic patients, and analyze its prognostic implications.

**Methods:** This retrospective cross-sectional study analyzed all admitted patients with confirmed COVID-19 in the emergency department of the Farhat Hached University Hospital in Sousse from April 1, 2020, to December 31, 2021.

**Results:** Out of the 2106 COVID-19 patients, 688 (32.8%) had diabetes. Among these patients, diabetes was pre-existing in 88.1% of cases, while it was inaugural in 11.9%. Our study revealed that diabetes was a poor prognostic factor in COVID-19 cases, associated with up to 1.72 (95% CI 1.41-2.1) times greater risk of severe or fatal forms. This may be due to several factors associated with the diabetic population, including advanced age ( $p=0.001$ ), the presence of underlying comorbidities ( $p=0.001$ ), and the presence of hemodynamic instability upon admission ( $p=0.001$ ). They also exhibited an increased risk of respiratory acidosis ( $p=0.001$ ) and AKI ( $p=0.0001$ ). Outcomes were less favorable in diabetic patients, with a final hospital mortality rate of 33.9% vs 22.9% in non-diabetic patients ( $p=0.0001$ ).

**Conclusion:** Diabetes is one of the comorbidities most associated with the severity of COVID-19 infection. Careful management of diabetic patients with COVID-19 is essential to prevent complications and reduce adverse outcomes.

**Keywords:** covid19; outcomes; diabetes mellitus; mortality

## **Introduction**

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has significantly affected millions of lives worldwide, with its repercussions extending beyond the realm of public health to encompass socioeconomic, psychological, and healthcare delivery aspects.

The emergence of the COVID-19 pandemic has not only posed unprecedented challenges to global healthcare systems but has also exposed the vulnerability of certain populations, including individuals with pre-existing health conditions such as diabetes.

As the world continues to grapple with the multifaceted impacts of the ongoing pandemic, understanding the intricate relationship between COVID-19 and diabetes has become increasingly imperative.

This heightened vulnerability highlights the need for targeted research to guide effective public health responses and clinical management strategies. While existing studies have shed light on the epidemiology and clinical outcomes of COVID-19 in diabetic patients, many questions remain unanswered—particularly regarding risk factors, disease progression, therapeutic approaches, and long-term sequelae specific to this population.

Therefore, this study aims to fill those knowledge gaps by examining the epidemiological, clinical, paraclinical, therapeutic, and prognostic aspects of COVID-19 in people with diabetes. Through detailed data analysis, it seeks to identify key

prognostic factors uniquely affecting this high-risk group, and to support more effective, tailored care strategies that can reduce complications and improve outcomes .

## **Methods**

This is a cross-sectional study designed to investigate the clinical outcomes of patients with RT-PCR-confirmed COVID-19, including those with diabetes, at the emergency department of the Farhat Hached university hospital from April 1, 2020, to December 31, 2021.

Patients aged 15 years or older hospitalized for severe acute respiratory syndrome related to SARS-CoV-2 infection associated with known or newly diagnosed diabetes, confirmed by detection of the SARS-CoV-2 viral genome in the upper airways by RT-PCR and/or chest CT findings suggestive of COVID-19 infection, and requiring hospitalization for the treatment for COVID-19 infection were included in the study. Patients with multiple missing data were excluded.

Data were collected using a data processing form from the patients' medical records.

The study collected data on sociodemographic characteristics (age, sex, comorbidities such as diabetes and hypertension, and lifestyle factors), clinical data (symptoms, physical examination findings and severity scores), paraclinical parameters (laboratory results, imagery findings, and biomarkers), therapeutic interventions (oxygen therapy, intubation, medications, and fluid management), and patient outcomes (length of stay, emergency department course, and final hospital disposition).

**Statistical Data Analysis** The data was analyzed using IBM SPSS software version 23.0 for windows.

Descriptive analysis included calculating frequencies and percentages for qualitative variables and means, standard deviations, medians, and ranges for quantitative variables. Analytical analysis consisted of Student's t-test for comparing means of two independent groups and Pearson's Chi-square test for frequency comparisons. Multivariate analysis was conducted using binary logistic regression to identify independent risk factors associated with disease severity in diabetic patients, incorporating variables with a univariate p-value < 0.2. The significance threshold for all tests was set at p<0.05.

## Results

A total of 2106 patients were enrolled in this study. The mean age was 64.48 $\pm$ 13.53 years, with extreme ages ranging from 16-95. The most prevalent age group was elderly >65 years (54.30%). The study population showed a male predominance (sex ratio 1.26) and a high prevalence of comorbidities, particularly hypertension (41.9%) and diabetes (32.8%). (table1)

**Table 1: characteristics of the study population**

|                             |                             | n(%)              |
|-----------------------------|-----------------------------|-------------------|
| Age (years)                 |                             |                   |
|                             | Mean $\pm$ SD               | 64.48 $\pm$ 13.53 |
|                             | Median [IQI]                | 66[56-74]         |
|                             | Min-max                     | 16-95             |
| Sex ratio (M/F)             |                             | 1.26              |
| Comorbidities               |                             | 1508(72.2)        |
|                             | Diabetes                    | 688(32.8)         |
|                             | Hypertension                | 882(42.1)         |
|                             | Coronary disease            | 244(11.6)         |
|                             | Obesity                     | 361(17.2)         |
|                             | Smoking                     | 378(18.0)         |
|                             | Chronic respiratory failure | 105(14.6)         |
|                             | Chronic kidney disease      | 140(6.7)          |
|                             | Tumors                      | 93(4.7)           |
|                             | Immunosuppressor therapy    | 74(3.5)           |
| Presenting symptoms         |                             |                   |
|                             | Dyspnea                     | 1578(75.3)        |
|                             | Fatigue                     | 1364(65.1)        |
|                             | Cough                       | 1385(66.1)        |
| Respiratory exam            |                             |                   |
| RR (cpm)                    | Median [IQI]                | 24[20-27]         |
|                             | Min-max                     | 11-50             |
| spO2 (%)                    | Median [IQI]                | 90[85-93]         |
|                             | Min-max                     | 22-100            |
| Hemodynamic assessment      |                             |                   |
| SBP (mm Hg)                 | Median [IQI]                | 130[120-140]      |
|                             | Min-max                     | 50-240            |
| HR (bpm)                    | Median [IQI]                | 88[80-100]        |
|                             | Min-max                     | 39-186            |
| GCS                         | <15                         | 109(5.2)          |
| Gasometrical values         |                             |                   |
| pH                          | Median [IQI]                | 7.42[7.38-7.46]   |
|                             | Min-max                     | 6.80-7.65         |
| paO2                        | Median [IQI]                | 69[59-86]         |
|                             | Min-max                     | 14-289            |
| pCO2                        | Median [IQI]                | 31[57-36]         |
|                             | Min-max                     | 9-90              |
| HCO3-                       | Median [IQI]                | 22.8[20.0-25.0]   |
|                             | Min-max                     | 3-35              |
| Chest CT lesion extent      |                             |                   |
|                             | 50-75%                      | 127(6.1)          |
|                             | <25%                        | 195(9.3)          |
|                             | 25-50%                      | 219(10.5)         |
|                             | >75%                        | 89(4.2)           |
| Oxygen Therapy/Ventilation  |                             | 1863(88.9)        |
| Nasal Cannulas              |                             | 1030(49.2)        |
| High-Concentration Mask     |                             | 660(31.5)         |
| Optiflow                    |                             | 82(3.9)           |
| Non-invasive Ventilation    |                             | 609(29.1)         |
| Intubation                  |                             | 25(1.2)           |
| ED LOS (days)               | Median [IQI]                | 8[3-12]           |
| ED mortality                |                             | 280(13.4)         |
| In-hospital referral        |                             | 1746(83.3)        |
| ICU need                    |                             | 312(14.89)        |
| Final Outcome               |                             |                   |
| Discharge                   |                             | 480(22.9)         |
| Total in-hospital mortality |                             | 583(27.8)         |

In a comparative analysis between 688 diabetic and 1418 non-diabetic patients admitted to our emergency department, diabetic individuals tended to be older, while non-diabetics were predominantly male. Moreover, diabetic patients exhibited a higher prevalence of comorbidities (74.1% vs 60.4%), particularly hypertension and renal failure, compared to their non-diabetic counterparts. Symptomatically, diabetics displayed a greater occurrence of respiratory distress such as dyspnea, cough, fever, and fatigue, while non-diabetics reported more issues related to smell and taste. Physiologically, diabetics typically had higher blood pressure levels, whereas non-diabetic patients showed more electrocardiogram abnormalities except for arrhythmias, which were more common in diabetics. Medical complications further distinguished the two groups, with diabetics being more prone to acute renal failure and non-diabetics to respiratory acidosis. Interestingly, imaging findings did not significantly differ between the groups. Treatment-wise, diabetic patients often required higher oxygen flow rates through a high-flow mask and were more likely to need curative and preventive anticoagulation, Calciparin, and antibiotic therapy. The mean and range of emergency department visits were similar between the two groups ( $p=0.113$  and  $p=0.599$ , respectively). However, the course of the emergency department hospitalization was less favorable for diabetic patients, with a worsening in diabetic patients ( $p=0.0001$ ) and a mortality rate of 19.2% compared to 10.4% for non-diabetic patients ( $p=0.0001$ ). The final outcome showed a higher mortality rate in diabetic patients (33.9%)

compared to non-diabetic patients (22.9%) ( $p=0.0001$ ) (table 2).

In the multivariate analysis, diabetes was associated with up to 1.72 times higher risk of severe or fatal disease when comparing survival and death rates between diabetic and non-diabetic patients ( $CI_{95\%}=1.41-2.10$ ,  $p=0.001$ ) (table 3).

## Discussion

Coronavirus disease (COVID-19), caused by SARS-CoV-2, exhibits a wide spectrum of severity, from asymptomatic to life-threatening respiratory distress. Elderly individuals and those with certain underlying conditions, notably diabetes, face an elevated risk of severe illness and mortality(1,2). Diabetes mellitus is prevalent among COVID-19 patients and is associated with higher rates of hospitalization, ICU admissions, complications, and mortality(3–7). Our study, encompassing 688 diabetic COVID-19 patients, revealed that advanced age, preexisting comorbidities along with clinical indicators are predictive of severity. Comparison with non-diabetic counterparts highlighted that diabetic patients were older with more comorbidities, particularly coronary artery disease, hypertension, and renal failure, and presented with more severe symptoms including dyspnea, cough, fever, and fatigue (8). They also exhibited higher rates of acute renal failure and required more aggressive therapeutic interventions, anticoagulation, and antibiotics. Notably, diabetic patients experienced a significantly higher case fatality rate both in the emergency department and throughout hospitalization, emphasizing the heightened risk associated with diabetes in the.

**Table 2: Results of the univariate analysis**

|                          |                             | Diabetic patients<br>n= 688 (%) | Non diabetic patients<br>n=1418 (%) | P         |
|--------------------------|-----------------------------|---------------------------------|-------------------------------------|-----------|
| Comorbidities            |                             | 510(74.1)                       | 857(60.4)                           | 0.001     |
| Coronaropathy            |                             | 117(17.0)                       | 127(9.0)                            | 0.001     |
| Hypertension             |                             | 436(63.4)                       | 446(31.5)                           | 0.001     |
| CKD                      |                             | 69(10.0)                        | 71(5.0)                             | 0.001     |
| Smoking                  |                             | 107(15.6)                       | 271(19.1)                           | 0.046     |
| Physical exam            |                             |                                 |                                     |           |
| Dyspnea                  |                             | 545(79.2)                       | 1033(72.8)                          | 0.002     |
| Cough                    |                             | 475(69.0)                       | 910(64.2)                           | 0.027     |
| Fever                    |                             | 379(55.1)                       | 658(46.4)                           | 0.001     |
| Fatigue                  |                             | 477(69.3)                       | 887(62.6)                           | 0.002     |
| Anosmia/Dysgeusia        |                             | 53(7.7)                         | 169(11.9)                           | 0.003     |
| BP                       | Mean                        | 132.13±17.675                   | 129.56±15.394                       |           |
|                          | Min-max                     | 80-240                          | 90-200                              | 0.001     |
| EKG                      | Normal                      | 580(84.3)                       | 1137(80.2)                          | 0.022     |
|                          | Sinus tachycardia           | 42(6.1)                         | 149(10.5)                           |           |
|                          | Repolarization disorders    | 33(4.8)                         | 65(4.6)                             |           |
|                          | Conduction disorders        | 23(3.3)                         | 51(3.6)                             |           |
|                          | Arrhythmia                  | 10(1.5)                         | 16(1.1)                             |           |
| Respiratory acidosis     |                             | 26(3.8)                         | 64(4.5)                             | 0.001     |
| AKI                      |                             | 198(28.8)                       | 219(15.4)                           | 0.001     |
| Oxygen therapy           | HFM                         | 238(34.6)                       | 422(29.8)                           | 0.025     |
|                          | No                          | 50(7.3)                         | 151(10.6)                           | 0.007     |
| Anti coagulation         | Enoxaparin                  | curative                        | 419(60.9)                           | 850(59.9) |
|                          |                             | preventive                      | 201(29.2)                           | 395(27.9) |
|                          | Calciparin                  | 15(2.2)                         | 11(0.8)                             |           |
|                          | HNF                         | 3(0.4)                          | 11(0.8)                             |           |
| Antibiotherapy           | No                          | 67(9.7)                         | 232(16.4)                           | 0.001     |
|                          | 3GC-ofloxacin               | 363(52.8)                       | 719(50.7)                           |           |
|                          | 3GC                         | 246(35.8)                       | 455(32.1)                           |           |
|                          | Amoxicillin-clavulanic acid | 12(1.7)                         | 12(0.8)                             |           |
| Outcomes                 | Stable                      | 318(46.2)                       | 604(42.6)                           | 0.001     |
|                          | Improvement                 | 212(30.8)                       | 575(40.6)                           |           |
|                          | Aggravation                 | 158(23)                         | 239(16.9)                           |           |
| In-hospital referral     |                             | 351(77.2)                       | 1212(85.4)                          | 0.001     |
| Discharge                |                             | 25(3.6)                         | 58(4.1)                             | 0.001     |
| Emergency mortality rate |                             | 132(19.2)                       | 148(10.4)                           | 0.001     |
| Final outcome            | Death                       | 233(33.9)                       | 325(22.9)                           | 0.001     |
|                          | Discharge                   | 455(66.1)                       | 1093(77.1)                          |           |

**Table3: Results of the multivariate analysis**

|                             | Surviving(%) | Deceased(%) | OddsRatio | IC 95%      | P     |
|-----------------------------|--------------|-------------|-----------|-------------|-------|
| Age>65                      | 64.5         | 35.5        | 5.54      | 2.07 - 9.10 | <10-3 |
| Cardiopathy                 | 64.6         | 35.4        | 1.64      | 1.29-2.09   | 0.01  |
| Diabete mellitus            | 65.8         | 34.2        | 1.72      | 1.41 - 2.10 | 0.01  |
| Choc signs                  | 21.5         | 78.50       | 1.32      | 1.11-2.88   | 0.01  |
| Glasgow coma score <13      | 33.9         | 66.10       | 2.22      | 1.71-2.88   | 0.01  |
| Acidosis                    | 50.9         | 49.10       | 1.52      | 1.37-1.69   | 0.01  |
| Acute renal failure         | 49.4         | 50.60       | 3.89      | 3.11-4.87   | 0.01  |
| Chest CT lesions extent>50% | 57.7         | 42.30       | 3.88      | 2.45-6.87   | <10-3 |

context of COVID-19. Multivariate analysis confirmed diabetes as an independent risk factor for severe or fatal disease.

With regard to average age, several studies of the diabetic population reported similar results, with diabetic patients being statistically older than non-diabetic patients(9–11).

Numerous studies have shown advanced age increases the risk of mortality (12–14). In regard to gender, studies show a male predominance(15,16). The male-related severity observed may be attributed to hormone-dependent modulation of ACE2 and TMPRSS2 expression, facilitating SARS-CoV-2 cellular entry, as well as higher prevalence of comorbidities like cardiovascular disease in males(17,18).

When it comes to comorbidities, diabetic patients exhibited higher comorbidity rates across multiple studies, particularly for hypertension and cardiovascular disease (19,20). Our study corroborates these findings, indicating significantly higher rates of hypertension and cardiovascular disease among diabetic patients ( $p=0.0001$ ).

Numerous studies have highlighted the association between comorbidities and the severity of COVID-19, with diabetes and hypertension being significant predictors of mortality in many cases, with multipliers ranging from 1.2 to 8.96 (21–25).

The initial finger-prick blood glucose levels upon admission in COVID-19 patients have been found

to exhibit a range of diabetic decompensations including inaugural diabetes (26–29).

Numerous studies have demonstrated the prognostic significance of glycemic control in COVID-19 patients. Hyperglycemia upon admission is associated with higher mortality rates and increased risk of complications such as acute respiratory distress syndrome(8,28,30).

In our study, diabetic decompensation upon admission was significantly associated with mortality in univariate analysis ( $p=0.02$ ), consistent with findings from other studies.

The biological data analysis in COVID-19 patients widely reported the presence of lymphopenia (106). Studies have reported varying prevalence rates, ranging from 29.8% to 55.4% in diabetic patients(8,10,31–34). Comparing diabetic and non-diabetic groups, lymphopenia was significantly more prevalent in the diabetic group (8,35).

Gazometric abnormalities, including respiratory alkalosis, respiratory acidosis, and metabolic alkalosis, have been frequently observed in COVID-19 patients. Studies have reported varying distributions of these abnormalities, with respiratory alkalosis being the most common(36–39). However, when comparing gazometric values between diabetic and non-diabetic patients, literature results have been inconsistent(19).

Other biological data were analyzed, including renal function, liver function, pancreatic enzymes, and inflammatory markers concluding that the diabetic group had higher rates of AKI compared



to non-diabetics while no statistically significant difference was found in liver function (8,11,12). Elevated inflammatory markers were noted in various studies(32,43,44). Patients with COVID-19 showed higher levels of CRP ( $p=0.06$ ) and interleukin-6 (IL-6) ( $p=0.07$ ) compared to non-diabetic patients(35,45).

CT scan findings have reportedly shown more severe lung lesions in diabetic patients(35,44,46–50), however our study did not find a significant difference ( $p=0.863$ ).

When it comes to oxygenation and ventilation, diabetic patients exhibited higher NIV usage compared to non-diabetics with usage rates ranging from 13.3% to 30.3% across different studies (19,28). Although some studies suggested greater intubation rates in diabetic patients(15), our study found similar rates between the two groups ( $p=0.944$ ).

Corticosteroid therapy remains controversial in COVID-19 treatment due to concerns about immunosuppression, delayed viral clearance, bacterial infections, and acute hyperglycemia(51,52). Their usage did not significantly differ between diabetic and non-diabetic patients in our study, consistent with findings from previous research(53). However, in diabetic patients, careful monitoring of blood glucose levels is essential due to their hyperglycemic potential (54,55).

Length of hospital stay is an important factor in COVID-19 outcomes, with prolonged stays associated with increased mortality risk(56). Studies differ on this finding, while length of stay

was statistically more prolonged in diabetic patients than in non-diabetic patients in some (8,28,57), it was comparable in others(19).

Regarding the outcome of COVID-19, diabetes significantly impacts the prognosis and progression of COVID-19, with studies consistently showing it as one of the most important comorbidities linked to disease severity. Early data from Wuhan, China, and international studies reported a prevalence of diabetes ranging from 12% to 25% in COVID-19 patients, with diabetes being associated with increased morbidity and mortality during previous viral pandemics(8,58).

Diabetes is associated with critical complications of COVID-19, such as acute respiratory distress syndrome (ARDS), the need for ICU admission, mechanical ventilation, and increased mortality rates. Studies comparing diabetic and non-diabetic COVID-19 patients consistently show a higher percentage of severe forms and ICU admissions among diabetics. Additionally, diabetic patients have a higher percentage of mortality following COVID-19 compared to non-diabetic patients(32,33,59–65).

## **Conclusion**

Our study found a substantial increase in the risk of critical COVID-19 infection among individuals with diabetes. The mortality rate was also significantly higher. Therefore, it is crucial to implement customized prevention and control measures to reduce the risk of viral transmission among vulnerable populations, and to tailor in hospital treatments to reduce mortality.

**Chatbot use:** An AI program (DeepL write) was used for linguistic correction and improving coherence of the manuscript.

**Conflict of interest and funding sources:** The authors declare no conflicts of interest and no funding sources for this study.

**Acknowledgement:** The authors would like to express their sincere gratitude to all the ED staff members of Farhat Hached University hospital of Sousse for their invaluable effort throughout the pandemic and the current study.

## References

1. Shekhar S. Copacino CE. Barrera FJ. Hall JE. Hannah-Shmouni F. Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders. *Ann Natl Acad Med Sci Avr.* 2020;56(2):112-5.
2. Zaki N. Alashwal H. Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. *Diabetes Metab Syndr.* 2020;14(5):1133-42.
3. Al-Sabah S. Al-Haddad M. Al-Youha S. Jamal M. Almazeedi S. COVID-19: Impact of obesity and diabetes on disease severity. *Clin Obes Déc.* 2020;10(6).
4. Saha A. Ahsan MM. MdTU Q. Naher S. Akter F. Mehedi HMH. Clinical characteristics and outcomes of COVID-19 infected diabetic patients admitted in ICUs of the southern region of Bangladesh. *Diabetes Metab Syndr.* 2021;15(1):229-35.
5. Fox T. Ruddiman K. Lo KB. Peterson E. DeJoy R. Salacup G. The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis. *Acta Diabetol.* 2021;58(1):33-8.
6. Apicella M. Campopiano MC. Mantuano M. Mazoni L. Coppelli A. Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. *Lancet Diabetes Endocrinol* Sept. 2020;8(9):782-92.
7. Landstra CP. de Koning EJP. COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. *Front Endocrinol.* 2021;12:649525.
8. Zhang Y. Li H. Zhang J. Cao Y. Zhao X. Yu N. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. *Diabetes Obes Metab* Août. 2020;22(8):1443-54.
9. Smati S. Tramunt B. Wargny M. Gourdy P. Hadjadj S. Cariou B. COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. *Curr Diab Rep.* 2022;22(2):53-63.
10. Sonmez A. Demirci I. Haymana C. Tasci I. Dagdelen S. Salman S. Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia. *J Diabetes.* 2021;13(7):585-95.
11. Zhou W. Ye S. Wang W. Li S. Hu Q. Clinical Features of COVID-19 Patients with Diabetes and Secondary Hyperglycemia. *J Diabetes Res.* 2020;2020(3918723).
12. Zhou F. Yu T. Du R. Fan G. Liu Y. Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet Mars.* 2020;395(10229):1054-62.
13. Bonanad C. García-Blas S. Tarazona-Santabalbina F. Sanchis J. Bertomeu-González V. Fácila L. et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. *J Am Med Dir Assoc.* juill 2020;21(7):915-8.
14. Williamson EJ. Walker AJ. Bhaskaran K. Bacon S. Bates C. Morton CE. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. *Nature.* 2020;584(7821):430-6.
15. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. *Diabetol Avr.* 2021;64(4):778-94.
16. McGurnaghan SJ. Weir A. Bishop J. Kennedy S. Blackbourn LAK. McAllister DA. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. *Lancet Diabetes Endocrinol* Févr. 2021;9(2):82-93.
17. Gebhard C. Regitz-Zagrosek V. Neuhauser HK. Morgan R. Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differ* Déc. 2020;11(1).
18. Penna C. Mercurio V. Tocchetti CG. Pagliaro P. Sex-related differences in COVID-19 lethality. *Br J Pharmacol* Oct. 2020;177(19):4375-85.
19. Shi Q. Zhang X. Jiang F. Zhang X. Hu N. Bimu C. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study;
20. Shang J. Wang Q. Zhang H. Wang X. Wan J. Yan Y. The Relationship Between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China. *Am J Med Janv.* 2021;134(1).
21. Yu C. Lei Q. Li W. Wang X. Liu W. Fan X. Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China. *Am J Prev Med* Août. 2020;59(2):168-75.
22. Grasselli G. Greco M. Zanella A. Albano G. Antonelli M. Bellani G. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med.* 2020;180(10):1345-55.



23. Tian W. Jiang W. Yao J. Nicholson CJ. Li RH. Sigurslid HH. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J Med Virol* Oct. 2020;92(10):1875-83.
24. Usui R. Kanamori S. Aomori M. Watabe S. Analysis of COVID-19 mortality in patients with comorbidities in Côte d'Ivoire. *J Public Health Afr*. 25 oct 2022;13(3):1748.
25. Alguwaihes AM. Al-Softani ME. Megdad M. Albader SS. Alsari MH. Alelayan A. Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study. *Cardiovasc Diabetol*. 2020;19(205).
26. Armeni E. Aziz U. Qamar S. Nasir S. Nethaji C. Negus R. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. *Lancet Diabetes Endocrinol* Août. 2020;8(8):660-3.
27. Sathish T. Kapoor N. Cao Y. Tapp RJ. Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. *Diabetes Obes Metab* Mars. 2021;23(3):870-4.
28. Li H. Tian S. Chen T. Cui Z. Shi N. Zhong X. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. *Diabetes Obes Metab* Oct. 2020;22(10):1897-906.
29. Fadini GP. Morieri ML. Boscari F. Fioretto P. Maran A. Busetto L. et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. *Diabetes Res Clin Pract*. oct 2020;168:108374.
30. Coppelli A. Giannarelli R. Aragona M. Penno G. Falcone M. Tiseo G. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. *Diabetes Care*. 2020;43(10):2345-8.
31. Shahriarirad R. Khodamoradi Z. Erfani A. Hosseinpour H. Ranjbar K. Emami Y. et al. Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. *BMC Infect Dis*. 18 juin 2020;20(1):427.
32. Guan WJ. Ni ZY. Hu Y. Liang WH. Ou CQ. He JX. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 30 avr 2020;382(18):1708-20.
33. Wu C. Chen X. Cai Y. Xia J. Zhou X. Xu S. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 1 juill 2020;180(7):934-43.
34. Bhatraju PK. Ghassemieh BJ. Nichols M. Kim R. Jerome KR. Nalla AK. et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. *N Engl J Med*. 21 mai 2020;382(21):2012-22.
35. Guo W. Li M. Dong Y. Zhou H. Zhang Z. Tian C. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev*. 2020;36(7).
36. Chen T. Wu D. Chen H. Yan W. Yang D. Chen G. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 26 mars 2020;368:m1091.
37. Alfano G. Fontana F. Mori G. Giaroni F. Ferrari A. Giovanella S. Acid base disorders in patients with COVID-19. *Int Urol Nephrol*. 2022;54(2):405-10.
38. Sanghani H. Bansal S. Parmar V. et al. (July 10, 2022) Study of Arterial Blood Gas Analysis in Moderate-to-Severe COVID-19 Patients. *Cureus* 14(7): e26715. DOI 10.7759/cureus.26715
39. Bahloul M. Kharrrat S. Chtara K. Hafdh M. Turki O. Baccouche N. et al. Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia. *Acute Crit Care*. févr 2022;37(1):84-93.
41. Wu C. Chen X. Cai Y. Xia J. Zhou X. Xu S. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 1.
42. Olsen S. Identification of non-diabetic glomerular disease in renal biopsies from diabetics—a dilemma. *Nephrol Dial Transpl*. 1999;14(8):1846-9.
43. Xu J. Yang X. Yang L. Zou X. Wang Y. Wu Y. et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. *Crit Care Lond Engl*. 6 juill 2020;24(1):394.
44. Christanto AG. Komala Dewi D. Nugraha HG. Hikmat IH. Chest X-Ray pattern and lung severity score in COVID-19 patients with diabetes mellitus: A cross sectional study. *Clin Epidemiol Glob Health*. 2022;16:101107.
45. Muniyappa R. Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol-Endocrinol Metab*. 2020;318(5).
46. Rangankar V. Koganti DV. Lamghare P. Prabhu A. Dhulipala S. Patil P. et al. Correlation Between CT Severity Scoring and Diabetes Mellitus in Patients With COVID-19 Infection. *Cureus*. 2021 Dec 6.
47. Raghavendra CR. Yuvabalakumaran G. Rajan R. Sidhesh RM. Mathavi S. Evaluation of Covid Severity in Diabetic vs Non-Diabetic Individuals using CT Severity Score. *Indian J Sci Technol*. 12 mai 2022;15(17):806-10.
48. Lu X. Cui Z. Pan F. Li L. Li L. Liang B. Glycemic status affects the severity of coronavirus disease 2019 in patients with diabetes mellitus: an observational study of CT radiological manifestations using an artificial intelligence algorithm. *Acta Diabetol Mai*. 2021;58(5):575-86.
49. Gangadharan S. Parker S. Ahmed FW. Chest radiological finding of COVID-19 in patients with and without diabetes mellitus: Differences in imaging finding. *World J Radiol*. 2022;14(1):13-8.
50. Lu S. Xing Z. Zhao S. Meng X. Yang J. Ding W. Different Appearance of Chest CT Images of T2DM and

NDM Patients with COVID-19 Pneumonia Based on an Artificial Intelligent Quantitative Method. Shan PF Éditeur Int J Endocrinol. 2021;2021:1-6.

51. Matthay MA. Corticosteroids WKD. COVID-19 pneumonia. and acute respiratory distress syndrome. J Clin Invest. 2020;130(12):6218-21.

52. Noreen S. Maqbool M. A. Dexamethasone: Therapeutic potential. risks. and future projection during COVID-19 pandemic | Elsevier Enhanced Reader [Internet] [Internet]. 2021. Disponible sur: <https://doi.org/10.1016/j.ejphar.2021.173854>

53. Liu Z. Li J. Huang J. Guo L. Gao R. Luo K. et al. Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1.880 Cases in Leishenshan Hospital. Wuhan. Front Endocrinol. 2020;11:478.

54. Deng F. Gao D. Ma X. Guo Y. Wang R. Jiang W. Corticosteroids in diabetes patients infected with COVID-19. Ir J Med Sci Févr. 2021;190(1):29-31.

55. Mittal S. Madan K. Mohan A. Tiwari P. Hadda V. Diabetes in COVID-19: Steroid effect. J Med Virol Juill. 2021;93(7).

56. V CS. MC S. MP M. JAM G. JA P. Factors associated with mortality. length of hospital stay and diagnosis of COVID-19: Data from a field hospital. J Infect Public Health Juill. 2022;15(7):800-5.

57. Al-Salameh A. Lanoix J. Bennis Y. Andrejak C. Brochot E. Deschasse G. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. Diabetes Metab Res Rev Mars. 2021;37(3).

58. Yang X. Yu Y. Xu J. Shu H. Xia J. Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan. China: a single-centered. retrospective. observational study. Lancet Respir Med Mai. 2020;8(5):475-81.

59. Yang JK. Feng Y. Yuan MY. Yuan SY. Fu HJ. Wu BY. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic. 2006;Medicine.23(6):623-8.

60. Allard R. Leclerc P. Tremblay C. Tannenbaum TN. Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection. Diabetes Care. 2010;33(7):1491-3.

61. Badawi A. Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis | Elsevier Enhanced Reader [Internet] [Internet]. 2016. Disponible sur: <https://doi.org/10.1016/j.ijid.2016.06.015>

62. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States. February 12-March 28. 2020. MMWR Morb Mortal Wkly Rep. 3 avr 2020;69(13):382-6.

63. Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. The Lancet. 15 févr 2020;395(10223):497-506.

64. Wang D. Hu B. Hu C. Zhu F. Liu X. Zhang J. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan. China. JAMA. 17 mars 2020;323(11):1061-9.

65. Zhang JJ. Dong X. Cao YY. Yuan YD. Yang YB. Yan YQ. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan. China. Allergy. juill 2020;75(7):1730-41.